Treating prostate cancer with immunotherapy remains challenging. However, researchers at City of Hope have developed a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, and the initial results of the first-in-human PhaseRead More…
In recent years, Chimeric Antigen Receptor (CAR) technology has made significant progress in the treatment of hematologic malignancies, particularly in acute lymphoblastic leukemia (ALL), lymphoma, and plasma cell myeloma (PCM). However, theRead More…
Activated T cells with certain surface markers, such as checkpoint inhibitor proteins, are regulated by another type of immune system cell—natural killer (NK) cells. In this way, the body likely suppresses destructiveRead More…
T-cell receptor (TCR) gene therapy is a form of cellular immunotherapy where peripheral blood T cells from cancer patients are genetically engineered ex vivo to express tumor-specific TCRs before being reintroduced intoRead More…
Acute myeloid leukemia (AML) is an aggressive blood cancer caused by a plethora of genetic mutations acquired throughout one’s lifetime. One of these genes, the tumor suppressor gene TP53, plays a crucialRead More…
T-cell receptor-engineered T cells (TCR-T) represent a form of cellular immunotherapy and a subtype of adoptive cell transfer (ACT). It involves the identification and selection of TCR sequences capable of specifically bindingRead More…
In a recent study, researchers from the University of Texas MD Anderson Cancer Center in the United States reported favorable results from a Phase I/II clinical trial involving 37 patients with relapsedRead More…
The use of modified chimeric antigen receptor (CAR) T cells (CAR-T) in immunotherapy has significantly improved the survival rates of pediatric patients with relapsed leukemia. However, these therapies are not as effectiveRead More…
In a recent study, researchers from Stanford University in the United States collected data from previous studies on CAR-T cell therapy to investigate the reactivation of human herpesvirus 6 (HHV-6) in patientsRead More…
In recent years, scientists have harnessed the power of gene editing technology to reprogram immune cells into therapies capable of targeting cancer. However, these immunotherapies are not universally effective across all patientsRead More…